Skip to main content

How does Empaveli compare to Soliris?

Medically reviewed by Carmen Pope, BPharm. Last updated on April 4, 2025.

Official Answer by Drugs.com

Empaveli is a brand (trade) name for pegcetacoplan which is a PEGylated 40kDa polyethylene glycol linear small molecule that acts as a C3 complement inhibitor. It helps stop both intravascular hemolysis (IVH) (the destruction of red blood cells in the circulation) and extravascular hemolysis (EVH) (the breakdown of red blood cells in the spleen, bone marrow, or liver by macrophages).

Soliris is a brand (trade) name for eculizumab which is a monoclonal antibody that specifically binds to the complement protein C5 with high affinity, preventing it from splitting into C5a and C5b, which stops generation of the terminal complement complex C5b-9.

Is there a difference in side effects between Empaveli and Soliris?

Empaveli is more likely than Soliris to cause:

but less likely than Soliris to cause:

There were no cases of meningitis in either group.

71% of people receiving Empaveli experienced normalization of their lactate dehydrogenase levels (LDH) levels within the first 4 weeks that persisted for 16 weeks in one trial, compared to only 15% receiving Soliris.

What are Empaveli and Soliris used for?

Empaveli and Soliris are prescription medicines approved to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).

PNH is a rare acquired, life-threatening disease of the blood that is characterized by the destruction of red blood cells (hemolytic anemia), blood clots (thrombosis), and impaired bone marrow function.

Soliris may also be used to treat:

Empaveli is only approved to treat PNH.

Related questions

How are Empaveli and Soliris administered?

Empaveli is administered by subcutaneous (just under the skin) infusion and Soliris is given by intravenous infusion (into a vein).

People can be taught how to self-administer Empaveli, using the Empaveli injector which is a compact, wearable, circular device that is placed on your stomach at least 1 inch from your belly button or previous injection site. This allows the person to be mobile and continue light daily activities without having to sit still waiting for the infusion to finish. Empaveli can also be given subcutaneously by a healthcare provider as an infusion into a clear area of skin on a person’s stomach (avoiding the belly button), top of the thighs, hips, or upper arms.

Soliris is usually given by a healthcare professional.

Empaveli is administered every two weeks and Soliris is given weekly for the first 5 weeks, then two weekly thereafter.

Most patients who started on Soliris are encouraged to switch to Ultomaris, which is made by the same company. Ultomaris contains the same ingredient as Soliris (eculizumab) but as a long-acting formulation which only needs to be given 7 times a year (after the initial starting dose) in adults and children over 44 lb (20 kg). People switching from Soliris to Ultomiris should receive their starting dose of Ultomiris 2 weeks after the last dose of Soliris. Most Ultomaris infusions take less than 1 hour.

What do Empaveli and Soliris contain?

Empaveli contains pegcetacoplan and Soliris contains eculizumab.

How do Empaveli and Soliris work?

Both Empaveli and Soliris affect the complement system, which is a part of the immune system that enhances (or complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane, but they each work in a slightly different way.

Empaveli works higher in the complement system than Soliris, binding to complement protein C3 and preventing it from splitting into C3a and C3b. It is a PEGylated 40kDa polyethylene glycol linear small molecule. Empaveli helps stop both IVH (the destruction of red blood cells in the circulation) and EVH (the breakdown of red blood cells in the spleen, bone marrow, or liver by macrophages). Empaveli is the only treatment that targets C3 to help prevent both forms of red blood cell destruction (IVH and EVH).

Soliris is a monoclonal antibody that binds to complement protein C5 which is further down the complement system, preventing it from splitting into C5a and C5b, which stops generation of the terminal complement complex C5b-9. This helps to stop IVH, but not EVH.

References
  • Soliris Prescribing Information. https://alexion.us/-/media/alexion_global/documents/regulatory/north-america/usa/2024/english/soliris_uspi.pdf
  • Ultomiris Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761108s037lbl.pdf
  • Empaveli Prescribing Information. https://pi.apellis.com/files/PI_Empaveli.pdf
  • Hillmen P, Szer J, Wietz I, et al. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria N Engl J Med 2021;384:1028-37. DOI: 10.1056/NEJMoa2029073

Read next

How do Izervay and Syfovre compare?

Izervay (avacincaptad pegol) and Syfovre (pegcetacoplan) are injectable treatments for geographic atrophy (GA), a severe form of age-related macular degeneration (AMD) that causes progressive and irreversible vision loss. Continue reading

How is Empaveli administered?

Empaveli (pegcetacoplan) is given subcutaneously (this means under the skin) using the Empaveli injector or an infusion pump. The Empaveli injector is a compact, wearable, circular device that is placed on your stomach at least 1 inch from your belly button or previous injection site. Continue reading

How does Empaveli work?

Empaveli has effects on the complement system, which is a part of the immune system that enhances (or complements) the ability of antibodies and phagocytic cells to clear microbes and damaged cells from an organism, promote inflammation, and attack the pathogen's cell membrane. Empaveli binds to complement protein C3 and prevents C3 from splitting into C3a and C3b. This helps to stop intravascular hemolysis (IVH or the destruction of red blood cells in the circulation) and extravascular hemolysis (EVH or the breakdown of red blood cells in the spleen, bone marrow, or liver by macrophages). Empaveli is the only treatment that targets C3 and may prevent both forms of red blood cell destruction (IVH and EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Continue reading

See also:

Related medical questions

Drug information

Related support groups